News

Polykon Manufacturing LLC merges with Seppic Inc. and becomes Seppic Inc. Richmond

Since its opening in 2020 in Richmond, Virginia, the Polykon Manufacturing LLC facility has strengthened Seppic’s proximity to our North American customers and expanded our manufacturing capabilities. Effective January 1, 2024, Polykon Manufacturing LLC took the next step by merging with its parent company, Seppic Inc.

This change brings consistency to the organization of Seppic’s manufacturing facilities and supports the company’s strategy to deliver a simplified customer experience. Seppic continues to grow by addressing multiple markets around the world, always with the highest level of service, while strengthening its brand image in the United States.

Seppic Inc. Richmond produces in particular SEPIMAX ZEN™, SEPINOV™ EMT 10, SEPINOV™ WEO, SIMULGEL™ NS, or SIMULGEL INS 100™. As a major global player in rheology modifiers, the Seppic Group continually invests in its production facilities in the United States to provide a high level of service to its customers.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and